Prescription drug · NDA
Cardura (doxazosin) NDC 58151-075
Doxazosin mesylate 2 mg/1 · Tablet · Oral · Viatris Specialty LLC
NDC codes
FDA NDC DirectoryProduct information
- Brand name (proprietary)
- Cardura
- Generic name (nonproprietary)
- doxazosin
- Active ingredients
- Doxazosin mesylate — 2 mg/1
- Dosage form
- Tablet
- Route
- Oral
- Labeler
- Viatris Specialty LLC
- Product type
- Prescription drug
- Marketing category
- NDA — New Drug ApplicationApplication NDA 019668
- Marketing start
- Listing expires
- Other FDA classes
- Adrenergic alpha-Antagonists (Mechanism)
- Identifiers
- Product ID 58151-075_dd9e819b-5657-453a-86e8-9627df619d94SPL ID dd9e819b-5657-453a-86e8-9627df619d94SPL set ID 5e1f5e49-2da1-43ab-9795-228a8bcc5a82RxCUI 104367, 104368, 104369, 197625, 197626, 197627, 197628, 205544UNII 86P6PQK0MUUPC 0358151074013
- Pharmacologic class
- alpha-Adrenergic Blocker
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.
Product label
Current FDA label (SPL), effective .
Indications (excerpt from the label)
CARDURA is an alpha 1 adrenergic antagonist indicated for: • Signs and symptoms of Benign Prostatic Hyperplasia (BPH) ( 1.1 ) • Treatment of Hypertension ( 1.2 ) 1.1 Benign Prostatic Hyperplasia (BPH) CARDURA is indicated for the treatment of the signs and symptoms of BPH. 1.2 Hypertension CARDURA is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including this drug. Control of high blood pressure should be part of com…
Excerpt only. Read the full label for complete information.
Other NDCs under NDA 019668
Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.
| Product | Strength | Form · route | Labeler | Product NDC |
|---|---|---|---|---|
| Doxazosin mesylate | Doxazosin mesylate 2 mg/1 | TabletOral | Mylan Pharmaceuticals Inc. | 59762-1389 |
| Doxazosin mesylate | Doxazosin mesylate 1 mg/1 | TabletOral | Mylan Pharmaceuticals Inc. | 59762-1388 |
| Doxazosin mesylate | Doxazosin mesylate 4 mg/1 | TabletOral | Mylan Pharmaceuticals Inc. | 59762-1390 |
| Doxazosin mesylate | Doxazosin mesylate 8 mg/1 | TabletOral | Mylan Pharmaceuticals Inc. | 59762-1391 |
| Doxazosin | Doxazosin mesylate 2 mg/1 | TabletOral | Mylan Pharmaceuticals Inc. | 59762-2420 |
| Doxazosin | Doxazosin mesylate 4 mg/1 | TabletOral | Mylan Pharmaceuticals Inc. | 59762-2440 |
| Doxazosin mesylate | Doxazosin mesylate 4 mg/1 | TabletOral | Aphena Pharma Solutions - Tennessee, LLC | 71610-965 |
| Doxazosin | Doxazosin mesylate 8 mg/1 | TabletOral | Mylan Pharmaceuticals Inc. | 59762-2480 |
| Carduradoxazosin | Doxazosin mesylate 2 mg/1 | TabletOral | ROERIG | 0049-2512 |
| Carduradoxazosin | Doxazosin mesylate 4 mg/1 | TabletOral | ROERIG | 0049-2614 |
| Doxazosin | Doxazosin mesylate 8 mg/1 | TabletOral | Aphena Pharma Solutions - Tennessee, LLC | 71610-628 |
| Doxazosin | Doxazosin mesylate 4 mg/1 | TabletOral | Aphena Pharma Solutions - Tennessee, LLC | 71610-927 |
| Carduradoxazosin | Doxazosin mesylate 1 mg/1 | TabletOral | Viatris Specialty LLC | 58151-074 |
| Carduradoxazosin | Doxazosin mesylate 4 mg/1 | TabletOral | Viatris Specialty LLC | 58151-076 |
| Carduradoxazosin | Doxazosin mesylate 8 mg/1 | TabletOral | ROERIG | 0049-2716 |
| Carduradoxazosin | Doxazosin mesylate 8 mg/1 | TabletOral | Viatris Specialty LLC | 58151-077 |